We would love to hear your thoughts about our site and services, please take our survey here.
Ant15, s usual you are correct. PYC have worked with Merck & co in 2014.
https://www.physiomics.co.uk/disclosure-of-large-pharma-partner-merck-co/
Laura, sorry for doubting your acumen.
Thanks for your input.
Can i ask with your background, why in your opinion have the new CEO not bought any shares yet?
Steady buying all day, and as someone else suggested, this happened last Friday, but only difference is last Friday sellers arrived at the end & carried on during the week.
Hopefully this a turnaround?
You would have thought so Laura?
However, the lowly SP and near lack of interest in people buying these shares, along with only a trickle of deals, shows that either there is fierce competition within this particular market, or what PYC are offering is not (yet) needed by drug development companies or these companies are getting the data they need from other sources or in house?
PYC have said they are in the "sweet spot", yet this sweet spot has not amounted to much yet? Maybe the FDA's #ProjectOptimus can be the saviour?
I believe it was completed sometime ago,
https://www.physiomics.co.uk/wp-content/uploads/2019/04/2017-1-11-Company-Update-2.pdf
We are talking 2015-16 timelines here?
The candidate was CCT245737, which was renamed PNT737, then licensed out to Sierra by which time it was SRA737 https://www.edisongroup.com/research/sierra-oncology-returns-rights-to-sra737/31442/ Sierra bought out by GSK and then SRA737 rights were returned to SAR after GSK's purchase of Sierra. Or something along those lines!
What it does show is that PYC have been on this "Personal medicine" train for nearly a decade.
I have reached out to them, but apart from a cordial reply, nothing about the subject in hand.
I can only go on the reply JM gave to a IM some months ago about why BOD dont see buying stock as the best way to grow the business?
Be interesting to hear Ant15's take on this?
Meanwhile, are we heading sub 1p?
Ant, nice paragraph there.
Have you migrated here from elsewhere?
Am i right in thinking you may have some historical ties with the stock?
The drop yesterday was i think in part after a few days of selling. I did not see any B&I swaps going through, normally you can match largish trades, discounting a few shares per trade with a B&I.
We then had over 15 buys ranging from a few hundred to over 1 thousand £'s all very much needed, However, seeing trades of 250k+ is what is required.
AACR Annual meeting is in San Diego 5th to 10th April, i wonder if PYC will attend, or submit abstract?
Looking back through search engine, they partnered in 2004 / 2005
https://www.physiomics.co.uk/physiomics-and-bayer-launch-a-new-service/
Https://www.bayer.com/en/us/news-stories/fda-breakthrough-therapy-designation#:~:text=Berlin%2C%20Germany%2C%20February%2026%2C,tumors%20have%20activating%20HER2%20(ERBB2)
https://twitter.com/Bayer/status/1762054925838606679
Yesterday, Physiomics reposted ( retweeted) a post from Bayer. The Bayer post was sent out om X on the 26th Feb 2024.
In the post, about pipeline and FDA granting Tyrosine Kinase inhibitor for non small cell lung cancer.
I have not followed Physiomics for as long as some here. Have PYC worked with Bayer in the past? Was it anything to do with the TK inhibitor? Just found it intriguing that out of nowhere, PYC repost Bayer, which i also think is a first?
Some light reading.
https://www.linkedin.com/pulse/granulocyte-colony-stimulating-factor-g-csf-drugs-market/
The part of the article that i found interesting is "Another significant player in the market is Kyowa Kirin. This Japanese pharmaceutical company has a strong presence in the G-CSF drugs market with its product, Gran, which is used for the management of neutropenia." As far as i understand it, this is what PYC are striving for with the adaption of their dosing tool?
Only issue i have is he does not pronounce his G's at the end of words!
Jim, looked tired and miffed, like he did not want to be at the Q&A
I think that by the time the next Q&A comes round, Peter will be flying solo.
Either no one asked about BOD buying shares, or they decided not to answer those questions?
I also found the reply about Hitesh interesting. Many will know that Hitesh is the principal consultant, but has many fingers in many pies. I take it from that, that they want someone who is 110% committed to the job & not having their time divided by System forcasting etc.
They seem genuinely excited about this Bio-statistics venture.
Https://www.londonstockexchange.com/news-article/PYC/contract-award/16381053?showDisclaimer=true